LM-101 + toripalimab + rituximab

A combination regimen consisting of LM-101 (component unknown—no structured data was found on LM-101 in available sources), toripalimab, and rituximab. **Toripalimab** is a monoclonal antibody that selectively targets programmed death protein 1 (PD-1), blocking PD-1/PD-L1 interaction and restoring T-cell mediated anti-tumor response. Its approved and investigational uses are primarily in cancer immunotherapy, especially for metastatic or recurrent nasopharyngeal carcinoma, and it is being explored for a range of B-cell malignancies in combination with rituximab. **Rituximab** is an anti-CD20 monoclonal antibody used to target B-lymphocytes, depleting CD20-positive B-cells for diseases such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and various autoimmune disorders. The mechanism of action for both is immune modulation and direct anti-tumor effects; however, there is no published or regulatory information on LM-101, suggesting it is either an internal code for a novel agent, a device, or another experimental compound. The efficacy, mechanism, and identity of LM-101 remain undefined in these sources.